<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993470/" ref="ordinalpos=1389&amp;ncbi_uid=3596336&amp;link_uid=PMC2993470" image-link="/pmc/articles/PMC2993470/figure/F1/" class="imagepopup">Fig. 1. From: Functional Selectivity in Adrenergic and Angiotensin <span class="highlight" style="background-color:">Signaling</span> Systems. </a></div><br /><div class="p4l_captionBody">Collateral efficacy in GPCR signaling. In the traditional paradigm of linear efficacy, a given agonist or antagonist for a GPCR initiates or inhibits a signaling pathway before the process is terminated by regulatory proteins such as GRKs and Î²-arrestins. In collateral or pluridimensional efficacy, a given ligand may be an antagonist for one pathway whereas simultaneously permitting activation of other pathways through G protein-dependent and -independent signaling. Therefore, multiple functions may be seen via a single receptor-ligand interaction and a subsequent unique receptor conformation change.</div></div>